Clinical outcomes of acute stroke patients with atrial fibrillation

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 4, 2009, Pages 371-374

  Khoo, Chee W ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Atrial fibrillation; Intravenous tissue plasminogen activator; Stroke; Thrombolysis

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ACUTE DISEASE; ARTICLE; BRAIN HEMORRHAGE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONTINUOUS INFUSION; CONVALESCENCE; DISABILITY; FIBRINOLYTIC THERAPY; HEART ATRIUM FIBRILLATION; HUMAN; LOW DRUG DOSE; OUTCOME ASSESSMENT; PATIENT CARE; STROKE; STROKE PATIENT; SURVIVAL;

EID: 69549092107     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.11     Document Type: Article

References (23)

1. Feigin VL. Stroke epidemiology in the developing world. Lancet 365, 2160-2161 (2005).
2. National Collaborating Centre for Chronic Conditions. Stroke: Diagnosis and Initial Management of Acute Stroke and Transient Ischaemic Attack (TIA). Royal College of Physicians, London, UK (2008).
3. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet 371, 1612-1623 (2008).
4. National Collaborating Centre for Chronic Conditions. Atrial Fibrillation: National Clinical Guideline for Management in Primary and Secondary Care. Royal College of Physicians, London, UK (2006).
5. Kimura K, Iguchi Y, Shibazaki K, Iwanaga T, Yamashita S, Aoki J. IV t-PA therapy in acute stroke patients with atrial fibrillation. J. Neurol. Sci. 276, 6-8 (2009).
6. NINDS t-PA Stroke Study Group. Generalised efficacy of t-PA for acute stroke: subgroup analysis of the NINDS t-PA Stroke Trial. Stroke 28, 2119-2125 (1997).
7. NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischaemic stroke. N. Engl. J. Med. 333, 1581-1587 (1995).
8. NINDS rt-PA Stroke Trial Investigators and Coordinators. A systems approach to immediate evaluation and management of hyperacute stroke: experience at 8 centers and implications for community practice and patient care. Stroke 28, 1530-1540 (1997).
9. The NINDS rt-PA Stroke Study Group. Effect of rt-PA on ischemic stroke lesion by computed tomography. Stroke 31, 2912-2919 (2000).
10. Hacke W, Donnan G, Fieschi C et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS and NINDS rt-PA Stroke trials. Lancet 363, 768-774 (2004).
11. Fagan S, Morgenstern L, Petitta A et al.; and NINDS rt-PA Stroke Study Group. Cost-effectiveness of tissue plasminogen, activator for acute ischemic stroke. Neurology 50, 883-890 (1998).
12. Molina CA, Alexandrov AV, Demchuk AM, Saqqur M, Uchino K, Alvarez-Sabin J. Improving the predictive accuracy of recanalization on stroke outcome in patients treated with tissue plasminogen activator. Stroke 35, 151-156 (2004).
13. Zanerle A, Kiechl S, Spiegel M et al. Recanalization after thrombolysis in stroke patients: predictors and prognostic implications. Neurology 68, 39-44 (2007).
14. Molina CA, Montaner J, Arenillas JF, Ribo M, Rubiera M, Alvarez-Sabin J. Differential pattern of tissue plasminogen activator - induced proximal middle cerebral artery recanalization among stroke subtypes. Stroke 35, 486-490 (2004).
15. Kimura K, Iguchi Y, Yamashita S, Shibazaki K, Kobayashi K, Inoue T. Atrial fibrillation as an independent predictor for no early recanalization after IV-t-PA in acute ischemic stroke. J. Neurol. Sci. 267, 57-61 (2008).
16. Frankel MR, Morgenstern LB, Kwiatkowski T et al. Predicting prognosis after stroke: a placebo group analysis from the national institute of neurological disorders and stroke rt-PA stroke trial. Neurology 55, 952-959 (2000).
17. Brown DL, Johnston KC, Wagner DP, Haley EC Jr. Predicting major neurological improvement with intravenous recombinant tissue plasminogen activator treatment of stroke. Stroke 35, 147-150 (2004).
18. Yamaguchi T, Mori E, Minematsu K et al.; japan Alteplase Clinical Trial (J-ACT) Group. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 37, 1810-1815 (2006).
19. Hughes M, Lip GY; Guideline Developmenc Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb. Haemost. 99, 295-304 (2008).
20. Singer DE, Albers GW, Dalen J et al. Antithrombotic therapy in atrial fibrillation: American College of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 133, 546S-592S (2008).
21. Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke 39, 1901-1910 (2008).
22. Partington SL, Abid S, Teo K, Oczkowski W, O'Donnell MJ. Pre-admission warfarin use in patients with acute ischaemic stroke and atrial fibrillation: the appropriate use and barriers to oral anticoagulant therapy. Thromb. Res. 120, 663-669 (2007).
23. Glazer NL, Dublin S, Smith NL et al. Newly detected atrial fibrillation and compliance with antithrombotic guidelines. Arch. Intern. Med. 167, 246-252 (2007).